Reduction in acute filariasis morbidity during a mass drug administration trial to eliminate lymphatic filariasis in papua new guinea

PLoS Neglected Tropical Diseases

Volumn 5, Issue 7, 2011, Pages

  Tisch, Daniel J ^a   Alexander, Neal D E ^b,c   Kiniboro, Benson ^b   Dagoro, Henry ^b   Siba, Peter M ^b   Bockarie, Moses J ^b,d   Alpers, Michael P ^b,e   Kazura, James W ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^e CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLCARBAMAZINE; IVERMECTIN; ANTIFILARIAL AGENT;

ARTICLE; BREAST ENGORGEMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE TRANSMISSION; ERADICATION THERAPY; HUMAN; INFECTION RISK; LYMPHATIC FILARIASIS; MAJOR CLINICAL STUDY; MONOTHERAPY; MORBIDITY; PAPUA NEW GUINEA; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SCROTAL SWELLING; SINGLE DRUG DOSE; TREATMENT OUTCOME; ADOLESCENT; ADULT; ANIMAL; BREAST; CHILD; DRUG EFFECT; FEMALE; INCIDENCE; LIMB; MALE; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; SCROTUM; WUCHERERIA BANCROFTI;

ADOLESCENT; ADULT; ANIMALS; BREAST; CHILD; CHILD, PRESCHOOL; ELEPHANTIASIS, FILARIAL; EXTREMITIES; FEMALE; FILARICIDES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PAPUA NEW GUINEA; SCROTUM; WUCHERERIA BANCROFTI; YOUNG ADULT;

EID: 79960944410     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001241     Document Type: Article

References (40)

1. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, et al. (2006) Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 367: 992-999.
2. Tisch DJ, Bockarie MJ, Dimber Z, Kiniboro B, Tarongka N, et al. (2008) Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation. Am J Trop Med Hyg 78: 289-293.
3. Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, et al. (2002) Mass treatment to eliminate filariasis in Papua New Guinea. N Engl J Med 347: 1841-1848.
4. McPherson T, (2003) Impact on the quality of life of lymphoedema patients following introduction of a hygiene and skin care regimen in a Guyanese community endemic for lymphatic filariasis: A preliminary clinical intervention study. Filaria J 2: 1.
5. Narahari SR, Ryan TJ, Mahadevan PE, Bose KS, Prasanna KS, (2007) Integrated management of filarial lymphedema for rural communities. Lymphology 40: 3-13.
6. Wijesinghe RS, Wickremasinghe AR, Ekanayake S, Perera MS, (2007) Efficacy of a limb-care regime in preventing acute adenolymphangitis in patients with lymphoedema caused by bancroftian filariasis, in Colombo, Sri Lanka. Ann Trop Med Parasitol 101: 487-497.
7. Wilson SF, Guarner J, Valme AL, Louis-Charles J, Jones TL, et al. (2004) Histopathologic improvement with lymphedema management, Leogane, Haiti. Emerg Infect Dis 10: 1938-1946.
8. Dreyer G, Noroes J, Figueredo-Silva J, Piessens WF, (2000) Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol Today 16: 544-548.
9. Dreyer G, Medeiros Z, Netto MJ, Leal NC, de Castro LG, et al. (1999) Acute attacks in the extremities of persons living in an area endemic for bancroftian filariasis: differentiation of two syndromes. Trans R Soc Trop Med Hyg 93: 413-417.
10. Addiss DG, Brady MA, (2007) Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria J 6: 2.
11. Addiss DG, Louis-Charles J, Roberts J, Leconte F, Wendt JM, et al. (2010) Feasibility and effectiveness of basic lymphedema management in Leogane, Haiti, an area endemic for bancroftian filariasis. PLoS Negl Trop Dis 4: e668.
12. Lammie PJ, Cuenco KT, Punkosdy GA, (2002) The pathogenesis of filarial lymphedema: is it the worm or is it the host? Ann N Y Acad Sci 979: 131-142; discussion 188-196.
13. Pfarr KM, Debrah AY, Specht S, Hoerauf A, (2009) Filariasis and lymphoedema. Parasite Immunol 31: 664-672.
14. Nutman TB, (2001) Lymphatic filariasis: new insights and prospects for control. Curr Opin Infect Dis 14: 539-546.
15. Taylor MJ, (2002) A new insight into the pathogenesis of filarial disease. Curr Mol Med 2: 299-302.
16. Bennuru S, Nutman TB, (2009) Lymphangiogenesis and lymphatic remodeling induced by filarial parasites: implications for pathogenesis. PLoS Pathog 5: e1000688.
17. Joseph A, Mony P, Prasad M, John S, Srikanth, et al. (2004) The efficacies of affected-limb care with penicillin diethylcarbamazine, the combination of both drugs or antibiotic ointment, in the prevention of acute adenolymphangitis during bancroftian filariasis. Ann Trop Med Parasitol 98: 685-696.
18. Shenoy RK, Kumaraswami V, Suma TK, Rajan K, Radhakuttyamma G, (1999) A double-blind, placebo-controlled study of the efficacy of oral penicillin, diethylcarbamazine or local treatment of the affected limb in preventing acute adenolymphangitis in lymphoedema caused by brugian filariasis. Ann Trop Med Parasitol 93: 367-377.
19. Suma TK, Shenoy RK, Kumaraswami V, (2002) Efficacy and sustainability of a footcare programme in preventing acute attacks of adenolymphangitis in Brugian filariasis. Trop Med Int Health 7: 763-766.
20. Gasarasi DB, Premji ZG, Mujinja PG, Mpembeni R, (2000) Acute adenolymphangitis due to bancroftian filariasis in Rufiji district, south east Tanzania. Acta Trop 75: 19-28.
21. Babu BV, Nayak AN, Dhal K, (2005) Epidemiology of episodic adenolymphangitis: a longitudinal prospective surveillance among a rural community endemic for bancroftian filariasis in coastal Orissa, India. BMC Public Health 5: 50.
22. Gyapong JO, Gyapong M, Adjei S, (1996) The epidemiology of acute adenolymphangitis due to lymphatic filariasis in northern Ghana. Am J Trop Med Hyg 54: 591-595.
23. Alexander ND, Perry RT, Dimber ZB, Hyun PJ, Alpers MP, et al. (1999) Acute disease episodes in a Wuchereria bancrofti-endemic area of Papua New Guinea. Am J Trop Med Hyg 61: 319-324.
24. Bockarie MJ, Alexander ND, Hyun P, Dimber Z, Bockarie F, et al. (1998) Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Lancet 351: 162-168.
25. Das PK, Ramaiah KD, Augustin DJ, Kumar A, (2001) Towards elimination of lymphatic filariasis in India. Trends Parasitol 17: 457-460.
26. World Health Organization (2005) Report on the Scientific working group on Lymphatic filariasis. TDR/SWG/05 WHO, Geneva.
27. Alexander ND, Bockarie MJ, Kastens WA, Kazura JW, Alpers MP, (1998) Absence of ivermectin-associated excess deaths. Trans R Soc Trop Med Hyg 92: 342.
28. World Health Organization (1984) Lymphatic filariasis. Fourth report of the WHO Expert Committee on Filariasis. World Health Organ Tech Rep Ser 702: 3-112.
29. Bockarie M, Kazura J, Alexander N, Dagoro H, Bockarie F, et al. (1996) Transmission dynamics of Wuchereria bancrofti in East Sepik Province, Papua New Guinea. Am J Trop Med Hyg 54: 577-581.
30. Horton J, Witt C, Ottesen EA, Lazdins JK, Addiss DG, et al. (2000) An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology 121: S147-160.
31. Ciferri FE, Kessel JF, (1967) Relation of age, sex, and microfilaria density to treatment of sub-periodic filariasis with diethylcarbamazine. Am J Trop Med Hyg 16: 321-328.
32. Genton B, Smith T, Baea K, Narara A, al-Yaman F, et al. (1994) Malaria: how useful are clinical criteria for improving the diagnosis in a highly endemic area? Trans R Soc Trop Med Hyg 88: 537-541.
33. Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA, (2005) Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 6: 179-200.
34. Kyelem D, Biswas G, Bockarie MJ, Bradley MH, El-Setouhy M, et al. (2008) Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs. Am J Trop Med Hyg 79: 480-484.
35. Ottesen EA, (2000) The global programme to eliminate lymphatic filariasis. Trop Med Int Health 5: 591-594.
36. Ottesen EA, (2006) Lymphatic filariasis: Treatment, control and elimination. Adv Parasitol 61: 395-441.
37. Ottesen EA, Duke BO, Karam M, Behbehani K, (1997) Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 75: 491-503.
38. Ottesen EA, Hooper PJ, Bradley M, Biswas G, (2008) The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis 2: e317.
39. Dreyer G, Figueredo-Silva J, Carvalho K, Amaral F, Ottesen EA, (2001) Lymphatic filariasis in children: adenopathy and its evolution in two young girls. Am J Trop Med Hyg 65: 204-207.
40. Kerketta AS, Babu BV, Rath K, Jangid PK, Nayak AN, et al. (2005) A randomized clinical trial to compare the efficacy of three treatment regimens along with footcare in the morbidity management of filarial lymphoedema. Trop Med Int Health 10: 698-705.